Current Atherosclerosis Reports

, Volume 10, Issue 5, pp 398–404

Rosiglitazone and cardiovascular risk

Authors

    • Division of CardiologyCedars-Sinai Medical Center
  • George A. Diamond
Article

DOI: 10.1007/s11883-008-0062-7

Cite this article as:
Kaul, S. & Diamond, G.A. Curr Atheroscler Rep (2008) 10: 398. doi:10.1007/s11883-008-0062-7

Abstract

A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive.

Copyright information

© Current Medicine Group LLC 2008